ClinicalTrials.gg
CompletedNCT00689936FIRSTUpdated Nov 20, 2019Results posted

Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma

A Phase 3 interventional study of Lenalidomide and low-dose dexamethasone and Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles in Multiple Myeloma, sponsored by Celgene. Completed at 288 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-20.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,623
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 249 studies testing lenalidomide in Multiple Myeloma — 29 open to participants now, 70 under way, 14 of them phase 3. Lenalidomide · Multiple Myeloma.

Enrollment
3rd of 249
1,623 · median 50
Started
2008
with 15 others
Phase 3
44 of 249
3 open now
Registered
47th of 249
by date
Lead sponsor
14 of 249
Celgene

Among the 249 studies testing lenalidomide in Multiple Myeloma, this one is the 3rd largest by enrollment, is one of 16 that started in 2008, is one of 44 in phase 3, and was the 47th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

29 of the 249 studies testing lenalidomide in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 249 studies testing lenalidomide in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to compare the safety and efficacy of Lenalidomide plus low dose dexamethasone to that of the combination of melphalan, prednisone and thalidomide.

Read the detailed description

CC-5013-MM020/IFM 07-01 is a Phase III, multicenter, randomized, open-label, 3-arm study that will compare the efficacy and safety of two Lenalidomide plus low-dose dexamethasone regimens given for two different durations of time (i.e., until progressive disease [PD] or for up to a maximum of 18 four-week cycles) to that of MPT given for a maximum of 12 six-week cycles.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • newly diagnosed multiple myeloma
  • Lenalidomide
  • Revlimid
  • phase III
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must understand and voluntarily sign form
  2. Age ≥ 18 years at the time of signing consent
  3. Previously untreated, symptomatic multiple myeloma as defined by the 3 criteria below:

    • MM diagnostic criteria (all 3 required):
    • Monoclonal plasma cells in the bone marrow ≥10% and/or presence of a -proven plasmacytoma
    • Monoclonal protein present in the serum and/or urine
    • Myeloma-related organ dysfunction (at least one of the following) [C] Calcium elevation in the blood (serum calcium >10.5 mg/dl or ) [R] Renal insufficiency (serum creatinine >2 mg/dl) [A] Anemia ( \<10 g/dl or 2 g \< laboratory normal) [B] Lytic bone lesions or osteoporosis

    AND have by protein electrophoresis analyses as defined by the following:

    • IgG multiple myeloma: Serum monoclonal paraprotein (M-protein) level ≥ 1.0 g/dl or urine M-protein level ≥ 200 mg/24 hours
    • IgA multiple myeloma: Serum M-protein level ≥ 0.5 g/dl or urine M-protein level ≥ 200 mg/24 hours
    • IgM multiple myeloma (IgM M-protein plus lytic bone disease documented by skeletal survey plain films): Serum M-protein level ≥ 1.0 g/dl or urine M-protein level ≥ 200mg/24hours
    • IgD multiple myeloma: Serum M-protein level ≥ 0.05 g/dl or urine M-protein level ≥ 200 mg/24 hours
    • Light chain multiple myeloma: Serum M-protein level ≥ 1.0 g/dl or urine M-protein level ≥ 200 mg/24 hours

    AND are at least 65 years of age or older or, if younger than 65 years of age, are not candidates for stem cell transplantation because:

    • The patient declines to undergo stem cell transplantation or
    • Stem cell transplantation is not available to the patient due to cost or other reasons
  4. performance status of 0, 1, or 2
  5. Able to adhere to the study visit schedule and other protocol requirements
  6. Females of (FCBP)\^2:

    1. Must agree to undergo two medically supervised pregnancy tests prior to starting study therapy with either Rd or MPT. The first pregnancy test will be performed within 10-14 days prior to the start of Rd or MPT and the second pregnancy test will be performed within 24 hours prior to the start of Rd or MPT. She must also agree to ongoing pregnancy testing during the course of the study and after the end of study therapy. This applies even if the patient practices complete and continued sexual abstinence.
    2. Must commit to either continued abstinence from heterosexual intercourse (which must be reviewed on a monthly basis) or agree to use and be able to comply with effective without interruption, 28 days prior to starting study drug, during the study therapy (including during periods of dose interruptions), and for 28 days after discontinuation of study therapy.
  7. Male Patients:

    1. Must agree to use a condom during sexual contact with a FCBP, even if they have had a vasectomy, throughout study drug therapy, during any dose interruption and after cessation of study therapy.
    2. Must agree to not donate semen during study drug therapy and for a period after end of study drug therapy.
    3. Must practice complete abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 28 days following study drug discontinuation, even if he has undergone a successful vasectomy.
  8. All patients must:

    1. Have an understanding that the study drug could have a potential teratogenic risk.
    2. Agree to abstain from donating blood while taking study drug therapy and following discontinuation of study drug therapy.
    3. Agree not to share study medication with another person. All FCBP and male patients must be counseled about pregnancy precautions and risks of fetal exposure.

Exclusion criteria

Exclusion Criteria:

  1. Previous treatment with anti-myeloma therapy (does not include radiotherapy, bisphosphonates, or a single short course of [i.e., less than or equal to the equivalent of dexamethasone 40 mg/day for 4 days; such a short course of steroid treatment must not have been given within 14 days of randomization]).
  2. Any serious medical condition that places the patient at an unacceptable risk if he or she participates in this study. Examples of such a medical condition are, but are not limited to, patient with unstable cardiac disease as defined by: Cardiac events such as MI within the past 6 months, heart failure class III-IV, uncontrolled atrial fibrillation or hypertension; patients with conditions requiring chronic steroid or treatment, such as rheumatoid arthritis, multiple sclerosis and lupus, that likely need additional steroid or immunosuppressive treatments in addition to the study treatment.
  3. Pregnant or lactating females.
  4. Any of the following laboratory abnormalities:

    • (ANC) \< 1,000/µL (1.0 x 109/L)
    • Untransfused count \< 50,000 cells/µL (50 x 10\^9/L)
    • Serum /AST or SGPT/ALT > 3.0 x (ULN)
  5. Renal failure requiring hemodialysis or peritoneal dialysis.
  6. Prior history of , other than multiple myeloma, unless the patient has been free of the disease for ≥ 3 years. Exceptions include the following:

    • Basal cell carcinoma of the skin
    • Squamous cell carcinoma of the skin
    • Carcinoma in situ of the cervix
    • Carcinoma in situ of the breast
    • Incidental histological finding of prostate cancer (TNM stage of T1a or T1b)
  7. Patients who are unable or unwilling to undergo antithrombotic therapy.
  8. Peripheral neuropathy of > grade 2 severity.
  9. Known positivity or active infectious hepatitis, type A, B, or C. Primary AL (immunoglobulin light chain) amyloidosis and myeloma complicated by amyloidosis.

    • 1 A variety of other types of end organ dysfunctions can occasionally occur and lead to a need for therapy. Such dysfunction is sufficient to support classification as myeloma if proven to be myeloma-related.
    • 2 A FCBP is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy or 2) has not been naturally (i.e., amenorrhea following cancer therapy does not rule out ) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,623 participants (actual)

Study arms

  • Experimental
    Lenalidomide / Dexamethasone until disease progression

    Lenalidomide plus low-dose dexamethasone given until disease progression

    Drug: Lenalidomide and low-dose dexamethasone

  • Experimental
    Lenalidomide / Dexamethasone for 18 cycles

    Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles

    Drug: Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles

  • Active comparator
    Melphalan, Prednisone, and Thalidomide (MPT) for 12 cycles

    Combination of Melphalan, Prednisone and Thalidomide given for 12 six-week cycles

    Drug: Melphalan, Prednisone and Thalidomide

Interventions

  • DrugLenalidomide and low-dose dexamethasone

    Drug pages: Lenalidomide · Dexamethasone

    Lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg 20mg, or 25 mg capsules, given either days 1-21 of each 28 day cycles or given every other day for 21 days until documentation of PD. Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle up to disease progression

    Also known as: Revlimid

  • DrugLenalidomide plus low-dose dexamethasone given for 18 four-week cycles

    Drug page: Lenalidomide

    lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg, 20 mg or 25 mg capsules given on days 1-21 of each 28 day cycle or every other day for 21 days for 18 cycles. Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle for 18 cycles

    Also known as: Revlimid

  • DrugMelphalan, Prednisone and Thalidomide

    Drug pages: Melphalan · Prednisone · Thalidomide

    Melphalan - oral, 2mg tablets dosed at either 0.25mg/kg, 0.125 mg/kg, 0.20mg/kg or 0.10mg/kg on days 1-4 of each 42 day cycle up to 12 cycles Prednisone - oral, 5mg, 10mg, 20 mg and 50 mg tablets dosed at 2mg/kg daily days 1-4 of each 42 day cycle for up to 12 cycles Thalidomide - oral, 50mg, 100mg and 200 mg capsules dosed at either 100mg or 200 mg daily on days 1-41 of each 42 day cycle for up to 12 cycles

    Also known as: Prednisone, Thalomid

06

What researchers measure

Primary outcomes

  1. Kaplan-Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Independent Review Adjudication Committee (IRAC)

    PFS was calculated as the time from randomization to the first documented PD or death due to any cause during the study, which ever occurred first based on the International Myeloma Working Group Uniform Response criteria (IMWG). Those who withdrew for any reason or received another anti-myeloma therapy without documented PD were censored on the date of their last response assessment, prior to receiving any other anti-myeloma therapy. Censoring rules for PFS: - No baseline assessments and no progression or death documented within the 2 scheduled assessments; Death within the lst two assessments without any adequate response assessment; Progression documented between scheduled assessments; Death between adequate assessments; no progression; study discontinuations for reasons other than PD or death; new anti-myeloma started prior to PD; death or PD after an extended lost to follow-up time period (2 or more missed scheduled assessment's).

    Time frame: From date of randomization until the data cut-off date of 24 May 2013. Median follow-up time for all participants was 17.1 months.

  2. Kaplan-Meier Estimates of PFS Based on the Response Assessment by the Investigator At the Time of Final Analysis

    PFS was calculated as the time from randomization to the first documented PD or death due to any cause during the study, which ever occurred first based on the International Myeloma Working Group Uniform Response criteria (IMWG). Those who withdrew for any reason or received another anti-myeloma therapy without documented PD were censored on the date of their last response assessment, prior to receiving any other anti-myeloma therapy. Censoring rules for PFS: - No baseline assessments and no progression or death documented within the 2 scheduled assessments; Death within the lst two assessments without any adequate response assessment; Progression documented between scheduled assessments; Death between adequate assessments; no progression; study discontinuations for reasons other than PD or death; new anti-myeloma started prior to PD; death or PD after an extended lost to follow-up time period (2 or more missed scheduled assessment's).

    Time frame: From date of randomization to date of data cut-off date of 21 January 2016; median follow-up for all participants was 17.7 months

Secondary outcomes

  1. Kaplan Meier Estimates of Overall Survival at the Time of Final Analysis (OS)

    Overall survival was defined as the time between randomization and death. Participants, who died, regardless of the cause of death, were considered to have had an event. All participants who were lost to follow-up prior to the end of the trial or who were withdrawn from the trial were censored at the time of last contact. Participants who were still being treated were censored at the last available date the participant was known to be alive.

    Time frame: From date of randomization to date of data cut-off date of 21 January 2016; median follow-up for all participants was 48.3 months

  2. Percentage of Participants With an Objective Response Based on IRAC Review

    Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined as: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.

    Time frame: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm

  3. Percentage of Participants With an Objective Response Based on Investigator Assessment at Time of Final Analysis

    Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined s: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.

    Time frame: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 21 January 2016; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm

  4. Kaplan Meier Estimates of Duration of Myeloma Response as Determined by the IRAC

    Duration of response was defined as the duration from the time when the response criteria were first met for CR or VGPR or PR based on IMWG criteria until the first date the response criteria were met for progressive disease or until the participant died from any cause, whichever occurred first.

    Time frame: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median follow-up for responders was 20.1 months

  5. Kaplan Meier Estimates of Duration of Myeloma Response as Determined by an Investigator Assessment at Time of Final Analysis

    Duration of response was defined as the duration from the time when the response criteria were first met for CR or VGPR or PR based on IMWG criteria until the first date the response criteria were met for progressive disease or until the participant died from any cause, whichever occurred first.

    Time frame: Disease response was assessed every 28 days until end of treatment; data cut-off date of 21 January 2016; median follow-up for responders was 19.9 months

  6. Time to First Response Based on the Review by the IRAC

    The time to first myeloma response was defined as the time from randomization to the time when the response criteria for at least a PR was first met based on the IMWG criteria.

    Time frame: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm

  7. Time to First Response Based on the Investigator Assessment at the Time of Final Analysis

    The time to first myeloma response was defined as the time from randomization to the time when the response criteria for at least a PR was first met based on the IMWG criteria assessed by the investigator.

    Time frame: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 21 January 2016; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm.

  8. Kaplan Meier Estimates of Time to Treatment Failure (TTF)

    TTF is defined as the time between the randomization and discontinuation of study treatment for any reason, including disease progression (determined by IRAC based on the IMWG response criteria), treatment toxicity, start of another anti-myeloma therapy (AMT) or death.

    Time frame: From date of randomization until the data cut-off of 24 May 2013; median follow-up for all participants was 16.1 months.

  9. Kaplan Meier Estimates of Time to Treatment Failure (TTF) at the Time of Final Analysis

    TTF is defined as the time between the randomization and discontinuation of study treatment for any reason, including disease progression (determined by the investigators assessment based on the IMWG response criteria), treatment toxicity, start of another anti-myeloma therapy (AMT) or death.

    Time frame: From date of randomization until the data cut-off date of 21 January 2016; median follow up for all participants was 16.1 months.

  10. Kaplan Meier Estimates for Time to Second-line Anti-myeloma Treatment (AMT)

    Time to second-line anti-myeloma therapy was defined as time from randomization to the start of another non-protocol anti-myeloma therapy.

    Time frame: From date of randomization until the data cut-off of 24 May 2013; median follow-up for all participants was 23.0 months

  11. Kaplan Meier Estimates of Time to Second Line Therapy AMT at the Time of Final Analysis

    Time to second-line anti-myeloma therapy is defined as time from randomization to the start of another non-protocol anti-myeloma therapy. Those who do not receive another anti-myeloma therapy were censored at the last assessment or follow-up visit known to have received no new therapy.

    Time frame: From date of randomization until the data cut-off of date 21 January 2016; median follow-up for all participants was 23.0 months

  12. Percentage of Participants With an Objective Response After Second-line Anti-myeloma Treatment at the Time of Final Analysis

    Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined s: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.

    Time frame: Disease response was assessed every 28 days until end of treatment; data cut-off date of 21 January 2016; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm

  13. Percentage of Participants With a Myeloma Response by Adverse Risk Cytogenetic Risk Category Based on IRAC Review.

    Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.

    Time frame: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm

  14. Percentage of Participants With a Myeloma Response by Favorable Hyperdiploidy Risk Cytogenetic Risk Category Based on IRAC Review

    Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.

    Time frame: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm

  15. Percentage of Participants With a Myeloma Response by Normal Risk Cytogenetic Risk Category Based on IRAC Review

    Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.

    Time frame: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm

  16. Percentage of Participants With a Myeloma Response by Uncertain Risk Cytogenetic Risk Category Based on IRAC Review

    Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.

    Time frame: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm

  17. Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Health Status Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in QOL or functioning and positive values indicate improvement.

    Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

  18. Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Physical Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.

    Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

  19. Change From Baseline in the EORTC QLQ-C30 Role Functioning Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Role Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.

    Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

  20. Change From Baseline in the EORTC QLQ-C30 Emotional Functioning Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Emotional Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.

    Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

  21. Change From Baseline in the EORTC QLQ-C30 Cognitive Functioning Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Cognitive Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.

    Time frame: Cycle 1 Day 1, (Baseline) then Months 1, 3, 6, 12, 18 and Discontinuation visit

  22. Change From Baseline in the EORTC QLQ-C30 Social Functioning Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Social Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.

    Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

  23. Change From Baseline in the EORTC QLQ-C30 Fatigue Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.

    Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation

  24. Change From Baseline in the EORTC QLQ-C30 Pain Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Pain Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.

    Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

  25. Change From Baseline in the EORTC QLQ-C30 Nausea/Vomiting Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Nausea/Vomiting Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.

    Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

  26. Change From Baseline in the EORTC QLQ-C30 Dyspnea Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnoea Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.

    Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

  27. Change From Baseline in the EORTC QLQ-C30 Insomnia Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Insomnia Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.

    Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

  28. Change From Baseline in the EORTC QLQ-C30 Appetite Loss Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Appetite Loss Scale is scored between 0 and 100, with a high score indicating a higher level of appetite loss. Negative change from Baseline values indicate improvement in appetite and positive values indicate worsening of appetite.

    Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

  29. Change From Baseline in the EORTC QLQ-C30 Constipation Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Constipation Scale is scored between 0 and 100, with a high score indicating a higher level of constipation. Negative change from Baseline values indicate improvement in constipation and positive values indicate worsening of constipation.

    Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

  30. Change From Baseline in the EORTC QLQ-C30 Diarrhea Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Diarrhea Scale is scored between 0 and 100, with a high score indicating a higher level of diarrhea. Negative change from Baseline values indicate improvement in diarrhea and positive values indicate worsening of diarrhea.

    Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

  31. Change From Baseline in the EORTC QLQ-C30 Financial Difficulties Domain

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Financial Difficulties Scale is scored between 0 and 100, with a high score indicating a higher level of financial difficulties. Negative change from Baseline values indicate improvement in financial difficulties and positive values indicate worsening of financial difficulties.

    Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

  32. Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Disease Symptoms Scale

    EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; a higher score indicates more severe disease symptom(s).

    Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

  33. Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Side Effects Treatment Scale

    EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; a higher score represents a more severe overall side effect of treatment.

    Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

  34. Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Future Perspective Scale

    EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; for the future perspective scale, a higher score indicates a better perspective of the future.

    Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

  35. Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Body Image Scale

    EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; for the body image scale, a higher score indicates a better body image.

    Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

  36. Change From Baseline in the European Quality of Life-5 Dimensions (EQ-5D) Health Utility Index Score

    EQ-5D is a self-administered questionnaire that assesses health-related quality of life. The EQ-5D descriptive health profile comprises five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 levels of response: No problem (1), some problems (2), and extreme problems (3). A unique EQ-5D health state is defined by combining one level from each of the five dimensions into a single utility index score. EQ-5D index values range from -0.59 to 1.00 where higher EQ-5D scores represent better health status. A positive change from baseline score indicates improvement in health status and better health state.

    Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

  37. Healthcare Resource Utilization (HRU): Rate of Inpatient Hospitalizations Per Year

    HRU was defined as any consumption of healthcare resources directly or indirectly related to the treatment of the patient. HRU Analysis may help in evaluating potential costs and budget impact of new treatments from a payer perspective. The rate of inpatient hospitalizations per patient year was calculated as the total number of hospitalizations divided by the total number of patient-years followed in the study period. Patient-years (PY) were calculated as the duration from baseline to last available HRQL assessment for each patient.

    Time frame: Day 1 (randomization) up to last visit completed 25 July 2016

  38. Number of Participants With Adverse Events (AEs) During the Active Treatment Phase

    A TEAE is any AE occurring or worsening on or after the first treatment of any study drug, and within 30 days after the last dose of the last study drug. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE. A serious AE is any AE occurring at any dose that: • Results in death; • Is life-threatening; • Requires or prolongs existing inpatient hospitalization; • Results in persistent or significant disability/incapacity; • Is a congenital anomaly/birth defect; • Constitutes an important medical event.

    Time frame: From first dose of study drug through 28 days following the discontinuation visit from active treatment phase; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm

  39. Shift From Baseline to Most Extreme Postbaseline Value in Creatinine Clearance (CrCl) During the Active Treatment Phase

    Renal function was assessed for participants from baseline to the most extreme value in creatinine clearance calculated using the Cockcroft-Gault estimation.

    Time frame: Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm

  40. Shift From Baseline to Most Extreme Postbaseline Value in Absolute Neutrophil Count During the Active Treatment Phase

    Neutrophil counts was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale.

    Time frame: Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm

  41. Shift From Baseline to Most Extreme Postbaseline Value in Hemoglobin During the Active Treatment Phase

    Hemoglobin was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale.

    Time frame: Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm

  42. Shift From Baseline to Most Extreme Postbaseline Value in Platelet Count During the Active Treatment Phase.

    Improvement in platelets was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale.

    Time frame: Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm

  43. Improvement of Infection Rate by Observing the Historical Data Compared to the Clinical Data Base

    Improvement of infection rate by observing historical data compared to the data within clinical database as not analyzed.

    Time frame: From randomization to 24 May 2013

07

Results

Posted Aug 11, 2017

Participant flow

This study was conducted in the Europe, Asia, North America and Pacific regions. Participants were randomized at 246 sites (165 in Europe, 23 in Asia, 39 in North America, and 19 in the Pacific). The study was co-sponsored by Intergroupe Francophone du Myélome (IFM) (for sites in France, Switzerland, and Belgium) and Celgene Corporation.

Active Treatment Phase
Participant flow — Active Treatment Phase
MilestoneLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Started535541547
Safety population532540541
Untreated316
Completed000
Not completed535541547
Withdrew: Adverse event687176
Withdrew: Disease progression273362339
Withdrew: Withdrawal by subject161621
Withdrew: Death602837
Withdrew: Lost to follow-up022
Withdrew: Protocol violation224
Withdrew: Study close out642621
Withdrew: Miscellaneous523447
Progression Free Survival-PFS-Follow-Up
Participant flow — Progression Free Survival-PFS-Follow-Up
MilestoneLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Started87300273
Completed87300273
Not completed000
Long-Term Follow Up Phase
Participant flow — Long-Term Follow Up Phase
MilestoneLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Started382463459
Completed255275315
Not completed127188144
Withdrew: Continue in long term follow up127188144

Outcome measures

PrimaryKaplan-Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Independent Review Adjudication Committee (IRAC)

PFS was calculated as the time from randomization to the first documented PD or death due to any cause during the study, which ever occurred first based on the International Myeloma Working Group Uniform Response criteria (IMWG). Those who withdrew for any reason or received another anti-myeloma therapy without documented PD were censored on the date of their last response assessment, prior to receiving any other anti-myeloma therapy. Censoring rules for PFS: - No baseline assessments and no progression or death documented within the 2 scheduled assessments; Death within the lst two assessments without any adequate response assessment; Progression documented between scheduled assessments; Death between adequate assessments; no progression; study discontinuations for reasons other than PD or death; new anti-myeloma started prior to PD; death or PD after an extended lost to follow-up time period (2 or more missed scheduled assessment's).

Time frame:
From date of randomization until the data cut-off date of 24 May 2013. Median follow-up time for all participants was 17.1 months.
Reported as:
Median · months
Kaplan-Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Independent Review Adjudication Committee (IRAC)
monthsLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Kaplan-Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Independent Review Adjudication Committee (IRAC)25.5 (20.7 to 29.4)20.7 (19.4 to 22.0)21.2 (19.3 to 23.2)
Statistical analysis
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Melphalan + Prednisone + Thalidomide (MPT) · Log Rank · p = 0.00006 (The p-value is based on the unstratified log-rank test.) · Hazard ratio (hr): 0.72 · 95% CI 0.61 to 0.85Based on stratified Cox proportional hazards model comparing the hazard functions associated with treatment groups.
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Lenalidomide and Dexamethasone Rd18 · Log Rank · p = 0.00001 (The p-value is based on the unstratified log-rank test.) · Hazard ratio (hr): 0.70 · 95% CI 0.60 to 0.82Based on stratified Cox proportional hazards model comparing the hazard functions associated with treatment groups.
  • Lenalidomide and Dexamethasone Rd18 vs Melphalan + Prednisone + Thalidomide (MPT) · Log Rank · p = 0.70349 (The p-value is based on the unstratified log-rank test.) · Hazard ratio (hr): 1.03 · 95% CI 0.89 to 1.20Based on stratified Cox proportional hazards model comparing the hazard functions associated with treatment groups.
PrimaryKaplan-Meier Estimates of PFS Based on the Response Assessment by the Investigator At the Time of Final Analysis

PFS was calculated as the time from randomization to the first documented PD or death due to any cause during the study, which ever occurred first based on the International Myeloma Working Group Uniform Response criteria (IMWG). Those who withdrew for any reason or received another anti-myeloma therapy without documented PD were censored on the date of their last response assessment, prior to receiving any other anti-myeloma therapy. Censoring rules for PFS: - No baseline assessments and no progression or death documented within the 2 scheduled assessments; Death within the lst two assessments without any adequate response assessment; Progression documented between scheduled assessments; Death between adequate assessments; no progression; study discontinuations for reasons other than PD or death; new anti-myeloma started prior to PD; death or PD after an extended lost to follow-up time period (2 or more missed scheduled assessment's).

Time frame:
From date of randomization to date of data cut-off date of 21 January 2016; median follow-up for all participants was 17.7 months
Reported as:
Median · months
Kaplan-Meier Estimates of PFS Based on the Response Assessment by the Investigator At the Time of Final Analysis
monthsLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Kaplan-Meier Estimates of PFS Based on the Response Assessment by the Investigator At the Time of Final Analysis26.0 (20.7 to 29.7)21.0 (19.7 to 22.4)21.9 (19.8 to 23.9)
Statistical analysis
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Melphalan + Prednisone + Thalidomide (MPT) · Log Rank · p = <0.00001 (The p-value is based on the unstratified log-rank test.) · Hazard ratio (hr): 0.69 · 95% CI 0.59 to 0.79Based on a stratified Cox proportional hazards model
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Lenalidomide and Dexamethasone Rd18 · Log Rank · p = <0.00001 (The p-value is based on the unstratified log-rank test.) · Hazard ratio (hr): 0.70 · 95% CI 0.60 to 0.81Based on a stratified Cox proportional hazards model
  • Lenalidomide and Dexamethasone Rd18 vs Melphalan + Prednisone + Thalidomide (MPT) · Log Rank · p = 0.91161 (The p-value is based on the unstratified log-rank test.) · Hazard ratio (hr): 0.99 · 95% CI 0.86 to 1.14Based on a stratified Cox proportional hazards model
SecondaryKaplan Meier Estimates of Overall Survival at the Time of Final Analysis (OS)

Overall survival was defined as the time between randomization and death. Participants, who died, regardless of the cause of death, were considered to have had an event. All participants who were lost to follow-up prior to the end of the trial or who were withdrawn from the trial were censored at the time of last contact. Participants who were still being treated were censored at the last available date the participant was known to be alive.

Time frame:
From date of randomization to date of data cut-off date of 21 January 2016; median follow-up for all participants was 48.3 months
Reported as:
Median · months
Kaplan Meier Estimates of Overall Survival at the Time of Final Analysis (OS)
monthsLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Kaplan Meier Estimates of Overall Survival at the Time of Final Analysis (OS)59.1 (53.9 to 65.9)62.3 (53.6 to 68.7)49.1 (44.3 to 53.5)
Statistical analysis
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Melphalan + Prednisone + Thalidomide (MPT) · Log Rank · p = 0.00234 (The p-value is based on the unstratified log-rank test.) · Hazard ratio (hr): 0.78 · 95% CI 0.67 to 0.92Based on a stratified Cox proportional hazards model
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Lenalidomide and Dexamethasone Rd18 · Log Rank · p = 0.82903 (The p-value is based on the unstratified log-rank test.) · Hazard ratio (hr): 1.02 · 95% CI 0.86 to 1.20Based on a stratified Cox proportional hazards model
  • Lenalidomide and Dexamethasone Rd18 vs Melphalan + Prednisone + Thalidomide (MPT) · Log Rank · p = 0.00119 (The p-value is based on the unstratified log-rank test.) · Hazard ratio (hr): 0.77 · 95% CI 0.66 to 0.90Based on a stratified Cox proportional hazards model
SecondaryPercentage of Participants With an Objective Response Based on IRAC Review

Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined as: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.

Time frame:
Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Reported as:
Number · percentage of participants
Percentage of Participants With an Objective Response Based on IRAC Review
percentage of participantsLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Percentage of Participants With an Objective Response Based on IRAC Review75.173.462.3
Statistical analysis
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Melphalan + Prednisone + Thalidomide (MPT) · Fisher Exact · p = <0.00001 · Odds ratio (or): 1.83 · 95% CI 1.41 to 2.37
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Lenalidomide and Dexamethasone Rd18 · Fisher Exact · p = 0.53065 · Odds ratio (or): 1.10 · 95% CI 0.83 to 1.44
  • Lenalidomide and Dexamethasone Rd18 vs Melphalan + Prednisone + Thalidomide (MPT) · Fisher Exact · p = 0.00010 · Odds ratio (or): 1.67 · 95% CI 1.29 to 2.15
SecondaryPercentage of Participants With an Objective Response Based on Investigator Assessment at Time of Final Analysis

Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined s: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.

Time frame:
Disease response was assessed every 28 days until end of treatment or the data cut-off date of 21 January 2016; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Reported as:
Number · percentage of participants
Percentage of Participants With an Objective Response Based on Investigator Assessment at Time of Final Analysis
percentage of participantsLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Percentage of Participants With an Objective Response Based on Investigator Assessment at Time of Final Analysis80.778.667.5
Statistical analysis
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Melphalan + Prednisone + Thalidomide (MPT) · Fisher Exact · p = <0.00001 · Odds ratio (or): 2.02 · 95% CI 1.53 to 2.68
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Lenalidomide and Dexamethasone Rd18 · Fisher Exact · p = 0.40500 · Odds ratio (or): 1.14 · 95% CI 0.85 to 1.54
  • Lenalidomide and Dexamethasone Rd18 vs Melphalan + Prednisone + Thalidomide (MPT) · Fisher Exact · p = 0.00004 · Odds ratio (or): 1.77 · 95% CI 1.35 to 2.32
SecondaryKaplan Meier Estimates of Duration of Myeloma Response as Determined by the IRAC

Duration of response was defined as the duration from the time when the response criteria were first met for CR or VGPR or PR based on IMWG criteria until the first date the response criteria were met for progressive disease or until the participant died from any cause, whichever occurred first.

Time frame:
Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median follow-up for responders was 20.1 months
Reported as:
Median · months
Kaplan Meier Estimates of Duration of Myeloma Response as Determined by the IRAC
monthsLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Kaplan Meier Estimates of Duration of Myeloma Response as Determined by the IRAC35.0 (27.9 to 43.4)22.1 (20.3 to 24.0)22.3 (20.2 to 24.9)
Statistical analysis
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Melphalan + Prednisone + Thalidomide (MPT) · Log Rank · p = <0.00001 (The p-value is based on the unstratified log-rank test.) · Hazard ratio (hr): 0.63 · 95% CI 0.51 to 0.76Based on unstratified Cox proportional hazards model.
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Lenalidomide and Dexamethasone Rd18 · Log Rank · p = <0.00001 (The p-value is based on the unstratified log-rank test.) · Hazard ratio (hr): 0.60 · 95% CI 0.50 to 0.72Based on unstratified Cox proportional hazards model.
  • Lenalidomide and Dexamethasone Rd18 vs Melphalan + Prednisone + Thalidomide (MPT) · Log Rank · p = 0.76740 (The p-value is based on the unstratified log-rank test.) · Hazard ratio (hr): 1.03 · 95% CI 0.86 to 1.23Based on unstratified Cox proportional hazards model.
SecondaryKaplan Meier Estimates of Duration of Myeloma Response as Determined by an Investigator Assessment at Time of Final Analysis

Duration of response was defined as the duration from the time when the response criteria were first met for CR or VGPR or PR based on IMWG criteria until the first date the response criteria were met for progressive disease or until the participant died from any cause, whichever occurred first.

Time frame:
Disease response was assessed every 28 days until end of treatment; data cut-off date of 21 January 2016; median follow-up for responders was 19.9 months
Reported as:
Median · months
Kaplan Meier Estimates of Duration of Myeloma Response as Determined by an Investigator Assessment at Time of Final Analysis
monthsLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Kaplan Meier Estimates of Duration of Myeloma Response as Determined by an Investigator Assessment at Time of Final Analysis31.5 (26.2 to 37.3)21.5 (19.2 to 23.0)22.1 (20.3 to 24.5)
Statistical analysis
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Melphalan + Prednisone + Thalidomide (MPT) · Log Rank · p = <0.00001 (The p-value is based on the unstratified log-rank test.) · Hazard ratio (hr): 0.61 · 95% CI 0.51 to 0.72Based on a stratified Cox proportional hazards model
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Lenalidomide and Dexamethasone Rd18 · Log Rank · p = <0.00001 (The p-value is based on the unstratified log-rank test.) · Hazard ratio (hr): 0.61 · 95% CI 0.52 to 0.72Based on a stratified Cox proportional hazards model
  • Lenalidomide and Dexamethasone Rd18 vs Melphalan + Prednisone + Thalidomide (MPT) · Log Rank · p = 0.99537 (The p-value is based on the unstratified log-rank test.) · Hazard ratio (hr): 1.00 · 95% CI 0.85 to 1.17Based on a stratified Cox proportional hazards model
SecondaryTime to First Response Based on the Review by the IRAC

The time to first myeloma response was defined as the time from randomization to the time when the response criteria for at least a PR was first met based on the IMWG criteria.

Time frame:
Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Reported as:
Median · months
Time to First Response Based on the Review by the IRAC
monthsLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Time to First Response Based on the Review by the IRAC1.8 (0.7 to 22.2)1.8 (0.8 to 17.1)2.8 (1.3 to 49.7)
Statistical analysis
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Melphalan + Prednisone + Thalidomide (MPT) · Wilcoxon (Mann-Whitney) · p = <0.00001
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Lenalidomide and Dexamethasone Rd18 · Wilcoxon (Mann-Whitney) · p = 0.46672
  • Lenalidomide and Dexamethasone Rd18 vs Melphalan + Prednisone + Thalidomide (MPT) · Wilcoxon (Mann-Whitney) · p = <0.00001
SecondaryTime to First Response Based on the Investigator Assessment at the Time of Final Analysis

The time to first myeloma response was defined as the time from randomization to the time when the response criteria for at least a PR was first met based on the IMWG criteria assessed by the investigator.

Time frame:
Disease response was assessed every 28 days until end of treatment or the data cut-off date of 21 January 2016; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm.
Reported as:
Median · months
Time to First Response Based on the Investigator Assessment at the Time of Final Analysis
monthsLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Time to First Response Based on the Investigator Assessment at the Time of Final Analysis1.8 (0.5 to 22.2)1.8 (0.8 to 34.8)2.8 (1.2 to 56.3)
Statistical analysis
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Melphalan + Prednisone + Thalidomide (MPT) · Wilcoxon (Mann-Whitney) · p = <0.00001
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Lenalidomide and Dexamethasone Rd18 · Wilcoxon (Mann-Whitney) · p = 0.46987
  • Lenalidomide and Dexamethasone Rd18 vs Melphalan + Prednisone + Thalidomide (MPT) · Wilcoxon (Mann-Whitney) · p = <0.00001
SecondaryKaplan Meier Estimates of Time to Treatment Failure (TTF)

TTF is defined as the time between the randomization and discontinuation of study treatment for any reason, including disease progression (determined by IRAC based on the IMWG response criteria), treatment toxicity, start of another anti-myeloma therapy (AMT) or death.

Time frame:
From date of randomization until the data cut-off of 24 May 2013; median follow-up for all participants was 16.1 months.
Reported as:
Median · months
Kaplan Meier Estimates of Time to Treatment Failure (TTF)
monthsLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Kaplan Meier Estimates of Time to Treatment Failure (TTF)16.9 (14.1 to 18.4)17.2 (14.6 to 18.2)14.1 (12.0 to 16.1)
Statistical analysis
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Melphalan + Prednisone + Thalidomide (MPT) · Log Rank · p = 0.00012 (The p-value is based on the unstratified log-rank test.) · Hazard ratio (hr): 0.77 · 95% CI 0.68 to 0.88Based on a stratified Cox proportional hazards model
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Lenalidomide and Dexamethasone Rd18 · Log Rank · p = 0.00187 (The p-value is based on the unstratified log-rank test.) · Hazard ratio (hr): 0.81 · 95% CI 0.71 to 0.93Based on a stratified Cox proportional hazards model
  • Lenalidomide and Dexamethasone Rd18 vs Melphalan + Prednisone + Thalidomide (MPT) · Log Rank · p = 0.45973 (The p-value is based on the unstratified log-rank test.) · Hazard ratio (hr): 0.95 · 95% CI 0.84 to 1.08Based on a stratified Cox proportional hazards model
SecondaryKaplan Meier Estimates of Time to Treatment Failure (TTF) at the Time of Final Analysis

TTF is defined as the time between the randomization and discontinuation of study treatment for any reason, including disease progression (determined by the investigators assessment based on the IMWG response criteria), treatment toxicity, start of another anti-myeloma therapy (AMT) or death.

Time frame:
From date of randomization until the data cut-off date of 21 January 2016; median follow up for all participants was 16.1 months.
Reported as:
Median · months
Kaplan Meier Estimates of Time to Treatment Failure (TTF) at the Time of Final Analysis
monthsLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Kaplan Meier Estimates of Time to Treatment Failure (TTF) at the Time of Final Analysis16.9 (14.1 to 18.4)17.2 (14.6 to 18.2)14.1 (12.0 to 16.1)
Statistical analysis
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Melphalan + Prednisone + Thalidomide (MPT) · Log Rank · p = 0.00002 (The p-value is based on the unstratified log-rank test.) · Hazard ratio (hr): 0.76 · 95% CI 0.67 to 0.86Based on a stratified Cox proportional hazards model
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Lenalidomide and Dexamethasone Rd18 · Log Rank · p = 0.00126 (The p-value is based on the unstratified log-rank test.) · Hazard ratio (hr): 0.81 · 95% CI 0.72 to 0.92Based on a stratified Cox proportional hazards model
  • Lenalidomide and Dexamethasone Rd18 vs Melphalan + Prednisone + Thalidomide (MPT) · Log Rank · p = 0.27704 (The p-value is based on the unstratified log-rank test.) · Hazard ratio (hr): 0.93 · 95% CI 0.83 to 1.06Based on a stratified Cox proportional hazards model
SecondaryKaplan Meier Estimates for Time to Second-line Anti-myeloma Treatment (AMT)

Time to second-line anti-myeloma therapy was defined as time from randomization to the start of another non-protocol anti-myeloma therapy.

Time frame:
From date of randomization until the data cut-off of 24 May 2013; median follow-up for all participants was 23.0 months
Reported as:
Median · months
Kaplan Meier Estimates for Time to Second-line Anti-myeloma Treatment (AMT)
monthsLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Kaplan Meier Estimates for Time to Second-line Anti-myeloma Treatment (AMT)39.1 (32.8 to NA)28.5 (26.9 to 30.4)26.7 (24.0 to 29.9)
Statistical analysis
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Melphalan + Prednisone + Thalidomide (MPT) · Log Rank · p = <0.00001 (The p-value is based on the unstratified log-rank test.) · Hazard ratio (hr): 0.66 · 95% CI 0.56 to 0.78Based on a stratified Cox proportional hazards model
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Lenalidomide and Dexamethasone Rd18 · Log Rank · p = 0.00067 (The p-value is based on the unstratified log-rank test.) · Hazard ratio (hr): 0.74 · 95% CI 0.63 to 0.88Based on a stratified Cox proportional hazards model
  • Lenalidomide and Dexamethasone Rd18 vs Melphalan + Prednisone + Thalidomide (MPT) · Log Rank · p = 0.12333 (The p-value is based on the unstratified log-rank test.) · Hazard ratio (hr): 0.88 · 95% CI 0.75 to 1.03Based on a stratified Cox proportional hazards model
SecondaryKaplan Meier Estimates of Time to Second Line Therapy AMT at the Time of Final Analysis

Time to second-line anti-myeloma therapy is defined as time from randomization to the start of another non-protocol anti-myeloma therapy. Those who do not receive another anti-myeloma therapy were censored at the last assessment or follow-up visit known to have received no new therapy.

Time frame:
From date of randomization until the data cut-off of date 21 January 2016; median follow-up for all participants was 23.0 months
Reported as:
Median · months
Kaplan Meier Estimates of Time to Second Line Therapy AMT at the Time of Final Analysis
monthsLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Kaplan Meier Estimates of Time to Second Line Therapy AMT at the Time of Final Analysis36.7 (31.9 to 45.2)28.5 (26.9 to 30.4)26.7 (24.0 to 29.1)
Statistical analysis
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Melphalan + Prednisone + Thalidomide (MPT) · Log Rank · p = <0.00001 (The p-value is based on the unstratified log-rank test.) · Hazard ratio (hr): 0.63 · 95% CI 0.54 to .73Based on unstratified Cox proportional hazards model.
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Lenalidomide and Dexamethasone Rd18 · Log Rank · p = 0.00001 (The p-value is based on the unstratified log-rank test.) · Hazard ratio (hr): 0.71 · 95% CI 0.61 to 0.83Based on unstratified Cox proportional hazards model.
  • Lenalidomide and Dexamethasone Rd18 vs Melphalan + Prednisone + Thalidomide (MPT) · Log Rank · p = 0.05821 (The p-value is based on the unstratified log-rank test.) · Hazard ratio (hr): 0.87 · 95% CI 0.76 to 1.00Based on unstratified Cox proportional hazards model.
SecondaryPercentage of Participants With an Objective Response After Second-line Anti-myeloma Treatment at the Time of Final Analysis

Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined s: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.

Time frame:
Disease response was assessed every 28 days until end of treatment; data cut-off date of 21 January 2016; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Reported as:
Number · percentage of participants
Percentage of Participants With an Objective Response After Second-line Anti-myeloma Treatment at the Time of Final Analysis
percentage of participantsLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Percentage of Participants With an Objective Response After Second-line Anti-myeloma Treatment at the Time of Final Analysis46.253.145.7
Statistical analysis
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Melphalan + Prednisone + Thalidomide (MPT) · Fisher Exact · p = 0.93824 · Odds ratio (or): 1.02 · 95% CI 0.75 to 1.38
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Lenalidomide and Dexamethasone Rd18 · Fisher Exact · p = 0.08836 · Odds ratio (or): 0.76 · 95% CI 0.56 to 1.03
  • Lenalidomide and Dexamethasone Rd18 vs Melphalan + Prednisone + Thalidomide (MPT) · Fisher Exact · p = 0.04974 · Odds ratio (or): 1.34 · 95% CI 1.01 to 1.79
SecondaryPercentage of Participants With a Myeloma Response by Adverse Risk Cytogenetic Risk Category Based on IRAC Review.

Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.

Time frame:
Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Reported as:
Number · Percentage of participants
Percentage of Participants With a Myeloma Response by Adverse Risk Cytogenetic Risk Category Based on IRAC Review.
Percentage of participantsLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Percentage of Participants With a Myeloma Response by Adverse Risk Cytogenetic Risk Category Based on IRAC Review.70.069.758.2
Statistical analysis
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Melphalan + Prednisone + Thalidomide (MPT) · Fisher Exact · p = 0.02134 · Odds ratio (or): 1.68 · 95% CI 1.08 to 2.59
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Lenalidomide and Dexamethasone Rd18 · Fisher Exact · p = 1.00000 · Odds ratio (or): 1.01 · 95% CI 0.64 to 1.59
  • Lenalidomide and Dexamethasone Rd18 vs Melphalan + Prednisone + Thalidomide (MPT) · Fisher Exact · p = 0.02374 · Odds ratio (or): 1.65 · 95% CI 1.08 to 2.53
SecondaryPercentage of Participants With a Myeloma Response by Favorable Hyperdiploidy Risk Cytogenetic Risk Category Based on IRAC Review

Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.

Time frame:
Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Reported as:
Number · percentage of participants
Percentage of Participants With a Myeloma Response by Favorable Hyperdiploidy Risk Cytogenetic Risk Category Based on IRAC Review
percentage of participantsLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Percentage of Participants With a Myeloma Response by Favorable Hyperdiploidy Risk Cytogenetic Risk Category Based on IRAC Review80.481.670.6
Statistical analysis
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Melphalan + Prednisone + Thalidomide (MPT) · Fisher Exact · p = 0.11152 · Odds ratio (or): 1.70 · 95% CI 0.91 to 3.21
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Lenalidomide and Dexamethasone Rd18 · Fisher Exact · p = 0.86336 · Odds ratio (or): 0.93 · 95% CI 0.47 to 1.83
  • Lenalidomide and Dexamethasone Rd18 vs Melphalan + Prednisone + Thalidomide (MPT) · Fisher Exact · p = 0.07321 · Odds ratio (or): 1.84 · 95% CI 0.96 to 3.55
SecondaryPercentage of Participants With a Myeloma Response by Normal Risk Cytogenetic Risk Category Based on IRAC Review

Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.

Time frame:
Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Reported as:
Number · percentage of particpants
Percentage of Participants With a Myeloma Response by Normal Risk Cytogenetic Risk Category Based on IRAC Review
percentage of particpantsLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Percentage of Participants With a Myeloma Response by Normal Risk Cytogenetic Risk Category Based on IRAC Review80.474.861.0
Statistical analysis
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Melphalan + Prednisone + Thalidomide (MPT) · Fisher Exact · p = 0.00043 · Odds ratio (or): 2.62 · 95% CI 1.55 to 4.45
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Lenalidomide and Dexamethasone Rd18 · Fisher Exact · p = 0.31274 · Odds ratio (or): 1.38 · 95% CI 0.78 to 2.43
  • Lenalidomide and Dexamethasone Rd18 vs Melphalan + Prednisone + Thalidomide (MPT) · Fisher Exact · p = 0.01936 · Odds ratio (or): 1.90 · 95% CI 1.13 to 3.19
SecondaryPercentage of Participants With a Myeloma Response by Uncertain Risk Cytogenetic Risk Category Based on IRAC Review

Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.

Time frame:
Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Reported as:
Number · percentage of participants
Percentage of Participants With a Myeloma Response by Uncertain Risk Cytogenetic Risk Category Based on IRAC Review
percentage of participantsLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Percentage of Participants With a Myeloma Response by Uncertain Risk Cytogenetic Risk Category Based on IRAC Review60.576.857.5
Statistical analysis
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Melphalan + Prednisone + Thalidomide (MPT) · Fisher Exact · p = 0.82128 · Odds ratio (or): 1.13 · 95% CI 0.46 to 2.80
  • Lenalidomide and Low-Dose Dexamethasone (Rd) vs Lenalidomide and Dexamethasone Rd18 · Fisher Exact · p = 0.11041 · Odds ratio (or): 0.46 · 95% CI 0.19 to 1.14
  • Lenalidomide and Dexamethasone Rd18 vs Melphalan + Prednisone + Thalidomide (MPT) · Fisher Exact · p = 0.07302 · Odds ratio (or): 2.44 · 95% CI 1.01 to 5.91
SecondaryChange From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Health Status Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in QOL or functioning and positive values indicate improvement.

Time frame:
Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Reported as:
Mean · units on a scale
Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Health Status Domain
units on a scaleLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Month 10.4 ± 23.98-1.3 ± 23.931.0 ± 23.68
Month 34.8 ± 24.154.7 ± 25.154.3 ± 26.04
Month 65.9 ± 25.935.4 ± 23.886.1 ± 25.98
Month 124.8 ± 26.423.2 ± 25.386.5 ± 25.90
Month 186.4 ± 28.025.7 ± 24.864.8 ± 27.05
Study discontinuation-0.1 ± 27.075.0 ± 27.330.3 ± 28.07
SecondaryChange From Baseline in the EORTC QLQ-C30 Physical Functioning Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Physical Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.

Time frame:
Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Reported as:
Mean · units on a scale
Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain
units on a scaleLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Month 1-1.7 ± 21.11-1.4 ± 19.56-0.9 ± 21.28
Month 33.4 ± 23.334.7 ± 22.942.2 ± 23.68
Month 64.7 ± 25.097.6 ± 22.855.3 ± 24.52
Month 125.0 ± 25.657.4 ± 23.406.9 ± 27.22
Month 186.9 ± 26.716.8 ± 23.588.3 ± 27.10
Discontinuation Visit-0.1 ± 29.703.0 ± 27.32-0.1 ± 27.58
SecondaryChange From Baseline in the EORTC QLQ-C30 Role Functioning Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Role Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.

Time frame:
Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Reported as:
Mean · units on a scale
Change From Baseline in the EORTC QLQ-C30 Role Functioning Domain
units on a scaleLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Month 1-2.7 ± 29.94-4.6 ± 28.20-2.4 ± 30.48
Month 32.4 ± 33.326.3 ± 32.434.1 ± 34.23
Month 66.3 ± 35.448.6 ± 32.428.2 ± 36.09
Month 127.8 ± 36.609.4 ± 34.1511.8 ± 38.94
Month 188.0 ± 35.349.1 ± 34.3514.5 ± 39.03
Discontinuation Visit-0.3 ± 39.583.8 ± 36.34-1.0 ± 38.41
SecondaryChange From Baseline in the EORTC QLQ-C30 Emotional Functioning Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Emotional Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.

Time frame:
Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Reported as:
Mean · units on a scale
Change From Baseline in the EORTC QLQ-C30 Emotional Functioning Domain
units on a scaleLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Month 10.6 ± 22.130.1 ± 20.731.0 ± 21.52
Month 33.8 ± 22.293.9 ± 22.112.1 ± 22.27
Month 64.6 ± 24.365.8 ± 22.395.5 ± 22.55
Month 124.6 ± 24.084.9 ± 22.235.1 ± 22.37
Month 185.8 ± 25.613.1 ± 23.315.1 ± 22.99
Discontinuation Visit2.6 ± 24.303.7 ± 23.77-0.0 ± 24.72
SecondaryChange From Baseline in the EORTC QLQ-C30 Cognitive Functioning Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Cognitive Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.

Time frame:
Cycle 1 Day 1, (Baseline) then Months 1, 3, 6, 12, 18 and Discontinuation visit
Reported as:
Mean · units on a scale
Change From Baseline in the EORTC QLQ-C30 Cognitive Functioning Domain
units on a scaleLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Month 1-1.2 ± 21.73-1.7 ± 19.08-1.8 ± 24.07
Month 3-0.7 ± 22.891.8 ± 20.94-1.5 ± 24.02
Month 6-0.9 ± 22.570.9 ± 19.77-0.3 ± 23.55
Month 12-1.6 ± 25.05-1.2 ± 20.19-0.6 ± 22.97
Month 18-2.2 ± 25.61-2.8 ± 20.97-0.7 ± 23.99
Discontinuation Visit-4.9 ± 27.57-2.6 ± 22.34-7.1 ± 25.15
SecondaryChange From Baseline in the EORTC QLQ-C30 Social Functioning Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Social Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.

Time frame:
Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Reported as:
Mean · units on a scale
Change From Baseline in the EORTC QLQ-C30 Social Functioning Domain
units on a scaleLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Month 1-4.3 ± 29.10-2.2 ± 27.44-1.4 ± 30.52
Month 30.7 ± 29.362.0 ± 30.932.4 ± 30.70
Month 64.0 ± 32.485.2 ± 28.503.4 ± 35.24
Month 122.9 ± 34.963.8 ± 32.295.8 ± 33.68
Month 184.2 ± 34.993.2 ± 31.676.0 ± 35.20
Discontinuation Visit-1.2 ± 33.502.7 ± 33.37-3.5 ± 33.20
SecondaryChange From Baseline in the EORTC QLQ-C30 Fatigue Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.

Time frame:
Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation
Reported as:
Mean · units on a scale
Change From Baseline in the EORTC QLQ-C30 Fatigue Domain
units on a scaleLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Month 12.6 ± 25.324.4 ± 24.032.8 ± 25.44
Month 3-2.5 ± 28.15-3.4 ± 25.16-1.8 ± 28.53
Month 6-3.7 ± 28.54-5.9 ± 26.37-4.5 ± 29.09
Month 12-4.3 ± 29.47-2.3 ± 26.63-3.9 ± 29.56
Month 18-3.1 ± 29.820.1 ± 29.12-4.3 ± 30.05
Discontinuation Visit0.3 ± 29.75-1.6 ± 29.112.7 ± 30.15
SecondaryChange From Baseline in the EORTC QLQ-C30 Pain Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Pain Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.

Time frame:
Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Reported as:
Mean · units on a scale
Change From Baseline in the EORTC QLQ-C30 Pain Domain
units on a scaleLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Month 1-5.4 ± 31.89-4.4 ± 30.70-7.8 ± 30.93
Month 3-13.4 ± 34.28-13.1 ± 32.32-12.1 ± 31.98
Month 6-14.4 ± 35.64-16.1 ± 33.44-13.4 ± 34.45
Month 12-14.0 ± 36.05-14.7 ± 32.34-14.3 ± 32.85
Month 18-14.4 ± 35.03-12.4 ± 35.28-14.7 ± 32.81
Discontinuation Visit-8.0 ± 39.37-7.9 ± 37.65-6.0 ± 37.09
SecondaryChange From Baseline in the EORTC QLQ-C30 Nausea/Vomiting Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Nausea/Vomiting Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.

Time frame:
Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Reported as:
Mean · units on a scale
Change From Baseline in the EORTC QLQ-C30 Nausea/Vomiting Domain
units on a scaleLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Month 11.8 ± 20.05-0.5 ± 23.194.0 ± 22.91
Month 3-1.1 ± 19.42-2.5 ± 21.92-1.2 ± 19.89
Month 6-1.3 ± 18.53-4.0 ± 21.52-3.9 ± 19.57
Month 12-2.2 ± 17.16-3.6 ± 18.86-3.9 ± 19.09
Month 18-2.3 ± 19.20-2.7 ± 18.92-3.9 ± 19.44
Discontinuation Visit0.4 ± 21.43-4.2 ± 24.371.0 ± 21.46
SecondaryChange From Baseline in the EORTC QLQ-C30 Dyspnea Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnoea Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.

Time frame:
Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Reported as:
Mean · units on a scale
Change From Baseline in the EORTC QLQ-C30 Dyspnea Domain
units on a scaleLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Month 10.9 ± 30.873.6 ± 29.854.2 ± 32.04
Month 3-0.8 ± 31.87-1.9 ± 29.452.0 ± 32.49
Month 6-2.3 ± 33.12-2.9 ± 29.660.1 ± 30.29
Month 12-3.5 ± 30.97-1.6 ± 29.23-1.6 ± 32.76
Month 18-1.8 ± 32.732.9 ± 28.330.4 ± 32.68
Discontinuation Visit-1.0 ± 37.420.8 ± 31.017.8 ± 33.72
SecondaryChange From Baseline in the EORTC QLQ-C30 Insomnia Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Insomnia Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.

Time frame:
Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Reported as:
Mean · units on a scale
Change From Baseline in the EORTC QLQ-C30 Insomnia Domain
units on a scaleLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Month 12.1 ± 33.343.2 ± 34.32-10.5 ± 30.47
Month 30.2 ± 35.11-1.3 ± 33.54-8.9 ± 35.28
Month 6-1.2 ± 34.84-1.9 ± 31.43-11.6 ± 32.96
Month 12-1.0 ± 34.781.1 ± 32.47-9.6 ± 31.00
Month 18-0.5 ± 37.111.4 ± 35.72-6.0 ± 34.42
Discontinuation Visit-5.2 ± 36.47-1.6 ± 31.27-4.5 ± 36.98
SecondaryChange From Baseline in the EORTC QLQ-C30 Appetite Loss Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Appetite Loss Scale is scored between 0 and 100, with a high score indicating a higher level of appetite loss. Negative change from Baseline values indicate improvement in appetite and positive values indicate worsening of appetite.

Time frame:
Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Reported as:
Mean · units on a scale
Change From Baseline in the EORTC QLQ-C30 Appetite Loss Domain
units on a scaleLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Month 11.3 ± 33.462.9 ± 31.871.0 ± 32.35
Month 3-5.9 ± 38.34-3.3 ± 35.25-6.2 ± 35.03
Month 6-9.8 ± 40.02-8.6 ± 33.98-13.5 ± 35.98
Month 12-7.3 ± 37.07-6.4 ± 35.30-10.5 ± 34.16
Month 18-8.1 ± 35.97-5.1 ± 33.29-12.2 ± 31.88
Discontinuation Visit-1.0 ± 36.77-7.5 ± 37.49-2.6 ± 37.18
SecondaryChange From Baseline in the EORTC QLQ-C30 Constipation Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Constipation Scale is scored between 0 and 100, with a high score indicating a higher level of constipation. Negative change from Baseline values indicate improvement in constipation and positive values indicate worsening of constipation.

Time frame:
Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Reported as:
Mean · units on a scale
Change From Baseline in the EORTC QLQ-C30 Constipation Domain
units on a scaleLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Month 18.3 ± 36.746.3 ± 36.1818.4 ± 41.23
Month 31.8 ± 37.530.0 ± 37.0213.9 ± 39.30
Month 6-2.4 ± 37.51-5.1 ± 37.396.8 ± 40.41
Month 12-2.4 ± 38.79-5.2 ± 38.093.7 ± 38.28
Month 18-4.5 ± 35.42-5.9 ± 36.650.0 ± 37.06
Discontinuation Visit-7.9 ± 39.98-7.5 ± 39.20-2.2 ± 38.86
SecondaryChange From Baseline in the EORTC QLQ-C30 Diarrhea Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Diarrhea Scale is scored between 0 and 100, with a high score indicating a higher level of diarrhea. Negative change from Baseline values indicate improvement in diarrhea and positive values indicate worsening of diarrhea.

Time frame:
Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Reported as:
Mean · units on a scale
Change From Baseline in the EORTC QLQ-C30 Diarrhea Domain
units on a scaleLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Month 13.8 ± 25.532.3 ± 24.94-0.6 ± 18.79
Month 33.7 ± 24.993.4 ± 27.27-2.4 ± 18.61
Month 68.2 ± 28.366.0 ± 27.95-2.2 ± 21.19
Month 1211.8 ± 31.359.1 ± 28.74-2.5 ± 17.26
Month 1814.8 ± 31.2010.9 ± 30.96-1.7 ± 17.46
Discontinuation Visit10.8 ± 29.566.4 ± 31.38-0.5 ± 19.39
SecondaryChange From Baseline in the EORTC QLQ-C30 Financial Difficulties Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Financial Difficulties Scale is scored between 0 and 100, with a high score indicating a higher level of financial difficulties. Negative change from Baseline values indicate improvement in financial difficulties and positive values indicate worsening of financial difficulties.

Time frame:
Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Reported as:
Mean · units on a scale
Change From Baseline in the EORTC QLQ-C30 Financial Difficulties Domain
units on a scaleLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Month 12.1 ± 21.43-0.3 ± 20.590.5 ± 22.98
Month 31.9 ± 23.09-0.4 ± 21.881.9 ± 21.48
Month 61.4 ± 22.92-0.3 ± 21.240.7 ± 24.57
Month 120.4 ± 23.991.6 ± 23.281.1 ± 23.16
Month 182.0 ± 22.231.8 ± 23.300.4 ± 21.20
Discontinuation Visit1.9 ± 27.190.5 ± 23.845.0 ± 24.82
SecondaryChange From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Disease Symptoms Scale

EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; a higher score indicates more severe disease symptom(s).

Time frame:
Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Reported as:
Mean · units on a scale
Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Disease Symptoms Scale
units on a scaleLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Month 1-4.0 ± 18.75-4.1 ± 19.37-4.4 ± 19.04
Month 3-9.1 ± 21.66-10.0 ± 19.97-7.0 ± 20.43
Month 6-8.8 ± 20.89-9.9 ± 20.94-7.9 ± 21.94
Month 12-7.8 ± 21.74-8.7 ± 20.29-6.5 ± 21.58
Month 18-8.7 ± 23.50-6.2 ± 23.30-7.9 ± 21.26
Discontinuation Visit-3.5 ± 24.82-4.5 ± 24.90-3.7 ± 23.54
SecondaryChange From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Side Effects Treatment Scale

EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; a higher score represents a more severe overall side effect of treatment.

Time frame:
Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Reported as:
Mean · units on a scale
Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Side Effects Treatment Scale
units on a scaleLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Month 12.5 ± 13.724.0 ± 14.895.6 ± 15.00
Month 31.0 ± 15.231.2 ± 14.673.5 ± 15.40
Month 61.7 ± 15.58-0.4 ± 14.392.9 ± 17.28
Month 121.9 ± 14.491.2 ± 16.204.7 ± 17.17
Month 182.2 ± 15.632.3 ± 17.364.3 ± 16.37
Discontinuation Visit0.6 ± 15.85-1.0 ± 15.813.8 ± 16.52
SecondaryChange From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Future Perspective Scale

EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; for the future perspective scale, a higher score indicates a better perspective of the future.

Time frame:
Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Reported as:
Mean · units on a scale
Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Future Perspective Scale
units on a scaleLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Month 14.7 ± 22.173.9 ± 20.943.3 ± 23.20
Month 38.5 ± 23.289.2 ± 22.956.3 ± 25.06
Month 69.8 ± 23.6712.3 ± 24.848.0 ± 25.26
Month 1210.8 ± 21.9012.1 ± 24.4110.0 ± 26.30
Month 1812.7 ± 23.9611.7 ± 24.769.5 ± 21.75
Discontinuation Visit5.8 ± 25.918.8 ± 26.713.2 ± 27.13
SecondaryChange From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Body Image Scale

EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; for the body image scale, a higher score indicates a better body image.

Time frame:
Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Reported as:
Mean · units on a scale
Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Body Image Scale
units on a scaleLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Month 1-4.5 ± 29.44-1.5 ± 27.19-1.6 ± 29.97
Month 3-1.7 ± 27.540.8 ± 26.23-3.0 ± 29.38
Month 6-1.4 ± 27.841.5 ± 29.72-2.8 ± 33.07
Month 12-1.4 ± 29.60-0.4 ± 31.64-2.6 ± 31.96
Month 18-2.3 ± 28.09-0.3 ± 31.04-1.1 ± 33.60
Discontinuation Visit-5.6 ± 34.291.8 ± 30.66-5.6 ± 33.73
SecondaryChange From Baseline in the European Quality of Life-5 Dimensions (EQ-5D) Health Utility Index Score

EQ-5D is a self-administered questionnaire that assesses health-related quality of life. The EQ-5D descriptive health profile comprises five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 levels of response: No problem (1), some problems (2), and extreme problems (3). A unique EQ-5D health state is defined by combining one level from each of the five dimensions into a single utility index score. EQ-5D index values range from -0.59 to 1.00 where higher EQ-5D scores represent better health status. A positive change from baseline score indicates improvement in health status and better health state.

Time frame:
Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Reported as:
Mean · units on a scale
Change From Baseline in the European Quality of Life-5 Dimensions (EQ-5D) Health Utility Index Score
units on a scaleLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Month 10.0 ± 0.29-0.0 ± 0.310.0 ± 0.28
Month 30.1 ± 0.330.1 ± 0.320.1 ± 0.32
Month 60.1 ± 0.320.1 ± 0.310.1 ± 0.34
Month 120.1 ± 0.330.1 ± 0.310.1 ± 0.35
Month 180.1 ± 0.360.1 ± 0.320.1 ± 0.35
Discontinuation Visit0.0 ± 0.400.0 ± 0.350.0 ± 0.39
SecondaryHealthcare Resource Utilization (HRU): Rate of Inpatient Hospitalizations Per Year

HRU was defined as any consumption of healthcare resources directly or indirectly related to the treatment of the patient. HRU Analysis may help in evaluating potential costs and budget impact of new treatments from a payer perspective. The rate of inpatient hospitalizations per patient year was calculated as the total number of hospitalizations divided by the total number of patient-years followed in the study period. Patient-years (PY) were calculated as the duration from baseline to last available HRQL assessment for each patient.

Time frame:
Day 1 (randomization) up to last visit completed 25 July 2016

No measurements were reported for this outcome.

SecondaryNumber of Participants With Adverse Events (AEs) During the Active Treatment Phase

A TEAE is any AE occurring or worsening on or after the first treatment of any study drug, and within 30 days after the last dose of the last study drug. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE. A serious AE is any AE occurring at any dose that: • Results in death; • Is life-threatening; • Requires or prolongs existing inpatient hospitalization; • Results in persistent or significant disability/incapacity; • Is a congenital anomaly/birth defect; • Constitutes an important medical event.

Time frame:
From first dose of study drug through 28 days following the discontinuation visit from active treatment phase; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Reported as:
Number · Participants
Number of Participants With Adverse Events (AEs) During the Active Treatment Phase
ParticipantsLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
≥ 1 adverse event (AE)529536539
≥ 1 grade (Gr) 3 or 4 AE453433480
≥ 1 grade (Gr) 5 AE503638
≥ 1 serious adverse event (SAE)359308270
≥ 1 AE related to Lenalidomide/Dex/Mel/Pred/Thal506501527
≥ 1 AE related to Lenalidomide4824810
≥ 1 AE related to dexamethasone4294100
≥ 1 AE related to melphalan00441
≥ 1 AE related to prednisone00326
≥ 1 AE related to thalidomide00493
≥1 AE related to Lenalidomide/Dex or Mel/Pred/Thal269269145
≥ 1 Gr 3 or 4 AE related to Len/Dex/Mel/Pred/Thal373326423
≥ 1 grade 3 or 4 AE related to Lenalidomide3422900
≥ 1 grade 3 or 4 AE related to dexamethasone2291770
≥ 1 grade 3 or 4 AE related to melphalan00307
≥ 1 grade 3 or 4 AE related to prednisone00118
≥ 1 grade 3 or 4 AE related to Thalidomide00316
≥1Gr 3 or 4 AE related to Len/Dex or Mel/Pred/Thal13110449
≥ 1 Grade 5 AE related to Len/Dex/Mel/Pred/Thal171110
≥ 1 Grade 5 AE related to Lenalidomide1290
≥ 1 Grade 5 AE related to Dexamethasone1670
≥ 1 Grade 5 AE related to melphalan006
≥ 1 Grade 5 AE related to prednisone005
≥ 1 Grade 5 AE related to Thalidomide005
≥1 Grade 5 AE related to Len/Dex or Mel/Pred/Thal1152
≥1 SAE related to Len/Dex/Mel/Pred/Thal195158142
≥1 SAE related to Lenalidomide1651300
≥1 SAE related to dexamethasone130970
≥1 SAE related to melphalan0075
≥1 SAE related to prednisone0062
≥1 SAE related to thalidomide0094
≥1 SAE related to Len/Dex or Mel/Pred/Thal956427
≥1AE leading to Len/Dex/Mel/Pred/Thal Withdrawal157109153
≥1 AE leading to Lenalidomide withdrawal109930
≥1 AE leading to dexamethasone withdrawal1521040
≥1 AE leading to melphalan withdrawal0083
≥1 AE leading to prednisone withdrawal0078
≥1 AE leading to Thalidomide withdrawal00146
≥1AE leading to Len/DexOR Mel/Pred/Thal Withdrawal968471
≥1AE leading to Len/Dex/Mel/Pred/Thal reduction279214348
≥1 AE leading to Lenalidomide reduction2031550
≥1 AE leading to dexamethasone reduction1701180
≥1 AE leading to melphalan reduction00199
≥1 AE leading to prednisone reduction0047
≥1 AE leading to thalidomide reduction00254
≥1AE leading to Len/Dex or Mel/Pred/Thal reduction30202
≥1 AE leading to Rd or MPT interruption368321419
≥1 AE leading to Lenalidomide interruption3533010
≥1 AE leading to dexamethasone interruption3192800
≥1 AE leading to melphalan interruption00328
≥1 AE leading to prednisone interruption00324
≥1 AE leading to Thalidomide interruption00388
≥1 AE leading to Len and Dex or MPT interruption290241249
SecondaryShift From Baseline to Most Extreme Postbaseline Value in Creatinine Clearance (CrCl) During the Active Treatment Phase

Renal function was assessed for participants from baseline to the most extreme value in creatinine clearance calculated using the Cockcroft-Gault estimation.

Time frame:
Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Reported as:
Number · participants
Shift From Baseline to Most Extreme Postbaseline Value in Creatinine Clearance (CrCl) During the Active Treatment Phase
participantsLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
CrCl< 30 mL/min to CrCl< 30 mL/min151719
CrCl < 30 mL/min to CrCl ≥ 30 but < 50 mL/min181419
CrCl < 30 mL/min to CrCl ≥ 50 but < 80 mL/min785
CrCl< 30 mL/min to ≥ 80 mL/min220
CrCl≥ 30 but < 50 mL/min to < 30 mL/min120
CrCl ≥ 30 but < 50 mL/min to CrCl ≥ 30 but < 50 mL374141
CrCl ≥ 30 but < 50 mL/min to CrCl ≥ 50 but < 80 mL675565
CrCl ≥ 30 but < 50 mL/min to ≥ 80 mL/min9122
CrCl ≥ 50 but < 80 mL to CrCl< 30 mL/min000
CrCl ≥ 50 but < 80 mL to CrCl ≥ 30 but < 50 mL/min414
CrCl ≥ 50 but < 80 mL to CrCl ≥ 50 but < 80 mL/min112130102
CrCl ≥ 50 but < 80 mL to ≥ 80 mL/min1079997
CrCl ≥ 80 mL/min to CrCl< 30 mL/min010
CrCl ≥ 80 mL/min to CrCl ≥ 30 but < 50 mL/min000
CrCl ≥ 80 mL/min to CrCl ≥ 50 but < 80 mL/min6109
CrCl ≥ 80 mL/min to CrCl ≥ 80 mL/min109114121
SecondaryShift From Baseline to Most Extreme Postbaseline Value in Absolute Neutrophil Count During the Active Treatment Phase

Neutrophil counts was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale.

Time frame:
Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Reported as:
Number · participants
Shift From Baseline to Most Extreme Postbaseline Value in Absolute Neutrophil Count During the Active Treatment Phase
participantsLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Normal Baseline Grade to Normal Postbaseline Grade10313337
Normal Baseline Grade to Grade 1 postbaseline968579
Normal Baseline Grade to Grade 2 postbaseline121109128
Normal Baseline Grade to Grade 3 postbaseline7071141
Normal Baseline Grade to Grade 4 postbaseline213045
Grade 1 Baseline to Normal postbaseline762
Grade1 Baseline to Grade 1 postbaseline8112
Grade 1 Baseline to Grade 2 postbaseline171511
Grade 1 Baseline to Grade 3 postbaseline253020
Grade 1 Baseline to Grade 4 postbaseline9421
Grade 2 Baseline to normal postbaseline100
Grade 2 Baseline to Grade 1 postbaseline111
Grade 2 Baseline to Grade 2 postbaseline14117
Grade 2 Baseline to Grade 3 postbaseline181821
Grade 2 Baseline to Grade 4 postbaseline9510
Grade 3 Baseline to Normal postbaseline000
Grade 3 Baseline to Grade 1 postbaseline000
Grade 3 Baseline to Grade 2 postbaseline210
Grade 3 Baseline to Grade 3 postbaseline220
Grade3 Baseline to Grade 4 postbaseline021
Grade 4 Baseline to Normal postbaseline Grade000
Grade 4 Baseline to Grade 1 postbaseline Grade100
Grade 4 Baseline to Grade 2 postbaseline000
Grade 4 Baseline Grade to Grade 3 postbaseline000
Grade 4 Baseline to Grade 4 postbaseline000
SecondaryShift From Baseline to Most Extreme Postbaseline Value in Hemoglobin During the Active Treatment Phase

Hemoglobin was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale.

Time frame:
Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Reported as:
Number · participants
Shift From Baseline to Most Extreme Postbaseline Value in Hemoglobin During the Active Treatment Phase
participantsLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Normal Baseline Grade to Normal Postbaseline Grade6109
Normal Baseline Grade to Grade 1 postbaseline393025
Normal Baseline Grade to Grade 2 postbaseline884
Normal Baseline Grade to Grade 3 postbaseline011
Normal Baseline Grade to Grade 4 postbaseline000
Grade 1 Baseline to Normal postbaseline000
Grade 1 Baseline to Grade 1 postbaseline106126110
Grade1 Baseline to Grade 2 postbaseline128123123
Grade 1 Baseline to Grade 3 postbaseline251720
Grade 1 Baseline to Grade 4 postbaseline254
Grade 2 Baseline to normal postbaseline000
Grade 2 Baseline to Grade 1 postbaseline81214
Grade 2 Baseline to Grade 2 postbaseline125135133
Grade 2 Baseline to Grade 3 postbaseline484147
Grade 2 Baseline to Grade 4 postbaseline4911
Grade 3 Baseline to Normal postbaseline000
Grade 3 Baseline to Grade 1 postbaseline010
Grade 3 Baseline to Grade 2 postbaseline12410
Grade 3 Baseline to Grade 3 postbaseline10810
Grade 3 Baseline to Grade 4 postbaseline532
Grade 4 Baseline to Normal postbaseline000
Grade 4 Baseline to Grade 1 postbaseline000
Grade 4 Baseline to Grade 2 postbaseline001
Grade 4 Baseline to Grade 3 postbaseline010
Grade 4 Baseline to Grade 4 postbaseline112
SecondaryShift From Baseline to Most Extreme Postbaseline Value in Platelet Count During the Active Treatment Phase.

Improvement in platelets was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale.

Time frame:
Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Reported as:
Number · participants
Shift From Baseline to Most Extreme Postbaseline Value in Platelet Count During the Active Treatment Phase.
participantsLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)
Normal Baseline Grade to Normal Postbaseline Grade197197165
Normal Baseline Grade to Grade 1 postbaseline216211208
Normal Baseline Grade to Grade 2 postbaseline243027
Normal Baseline Grade to Grade 3 postbaseline151231
Normal Baseline Grade to Grade 4 postbaseline4511
Grade1 Baseline to Normal postbaseline Grade136
Grade 1 Baseline to Grade 1 postbaseline343851
Grade 1 Baseline to Grade 2 postbaseline15197
Grade 1 Baseline to Grade 3 postbaseline101210
Grade 1 Baseline to Grade 4 postbaseline211
Grade 2 Baseline to normal postbaseline Grade000
Grade 2 Baseline to Grade 1 postbaseline012
Grade 2 Baseline to Grade 2 postbaseline331
Grade 2 Baseline to Grade 3 postbaseline322
Grade 2 Baseline to Grade 4 postbaseline102
Grade 3 Baseline to Normal postbaseline Grade000
Grade 3 Baseline to Grade 1 postbaseline000
Grade 3 Baseline to Grade 2 postbaseline001
Grade 3 Baseline to Grade 3 postbaseline001
Grade 3 Baseline to Grade 4 postbaseline210
SecondaryImprovement of Infection Rate by Observing the Historical Data Compared to the Clinical Data Base

Improvement of infection rate by observing historical data compared to the data within clinical database as not analyzed.

Time frame:
From randomization to 24 May 2013

No measurements were reported for this outcome.

Adverse events

Collected over From the first dose of treatment to at least 28 days after discontinuation of active treatment for those not continuing in the PFS phase; median duration of treatment was 80.2 weeks in the Rd arm, 72.0 weeks in the Rd18 arm and 67.1 weeks in the MPT arm.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenalidomide and Low-Dose Dexamethasone (Rd)—378/532 (71.1%)523/532 (98.3%)
Lenalidomide and Dexamethasone (Rd18)—308/540 (57%)532/540 (98.5%)
Melphalan + Prednisone + Thalidomide (MPT)—270/541 (49.9%)532/541 (98.3%)
Most frequent serious events
Showing 10 of 622
Most frequent serious events
EventLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone (Rd18)Melphalan + Prednisone + Thalidomide (MPT)
PNEUMONIAInfections and infestations60/53248/54035/541
ANAEMIABlood and lymphatic system disorders24/53215/54023/541
PYREXIAGeneral disorders22/53211/5408/541
BACK PAINMusculoskeletal and connective tissue disorders22/53219/54010/541
RENAL FAILURE ACUTERenal and urinary disorders21/53216/54010/541
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders20/53215/54020/541
DEEP VEIN THROMBOSISVascular disorders19/53211/5408/541
ATRIAL FIBRILLATIONCardiac disorders18/53212/5409/541
RENAL FAILURERenal and urinary disorders8/53218/54014/541
SEPSISInfections and infestations17/53210/5408/541
Most frequent other events
Showing 10 of 83
Most frequent other events
EventLenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone (Rd18)Melphalan + Prednisone + Thalidomide (MPT)
NEUTROPENIABlood and lymphatic system disorders194/532177/540325/541
CONSTIPATIONGastrointestinal disorders233/532210/540282/541
DIARRHOEAGastrointestinal disorders248/532205/54086/541
ANAEMIABlood and lymphatic system disorders237/532191/540219/541
OEDEMA PERIPHERALGeneral disorders220/532168/540213/541
PERIPHERAL SENSORY NEUROPATHYNervous system disorders113/53293/540191/541
FATIGUEGeneral disorders178/532176/540153/541
BACK PAINMusculoskeletal and connective tissue disorders175/532137/540115/541
NAUSEAGastrointestinal disorders156/532127/540163/541
INSOMNIAPsychiatric disorders150/532127/54053/541

Baseline characteristics

Intent to Treat (ITT) population includes all participants who were randomized, independent of whether they received study treatment or not

Age, Continuous
Age, Continuous(years)Lenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)Total
Mean73.2 ± 6.5772.9 ± 6.5073.1 ± 6.3273.1 ± 6.46
Sex: Female, Male
Sex: Female, Male(Participants)Lenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)Total
Female241268260769
Male294273287854
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Lenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)Total
Asian404344127
Black or African American96520
Native Hawaiian or other Pacific Islanders1012
White or Caucasian4744804911445
Other, Miscellaneous611320
Undisclosed5139
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Lenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)Total
Hispanic or Latino373336106
Not Hispanic or Latino4935055081506
Undisclosed53311
International Staging System (ISS)
International Staging System (ISS)(Participants)Lenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)Total
Stage I106106103315
Stage II227229225681
Stage III202206219627
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Lenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)Total
0 (fully active)155163156474
1 (restrictive but ambulatory)257263275795
2 (ambulatory but unable to work)119113111343
3-4 (limited self-care, completely disabled)2226
Missing2035
Creatinine clearance
Creatinine clearance(Participants)Lenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)Total
>=60 ml/min269280285834
<60 ml/min266261261788
Missing0011
Beta2 Microglobulin
Beta2 Microglobulin(Participants)Lenalidomide and Low-Dose Dexamethasone (Rd)Lenalidomide and Dexamethasone Rd18Melphalan + Prednisone + Thalidomide (MPT)Total
>5.5 mg/L224224234682
<=5.5 mg/L309316312937
Missing2114

4 further baseline measures are reported on the registry.

08

Study locations

288 sites
  • University of AL Birmingham
    Birmingham, Alabama 35294, United States
  • Cedar Sinai Medical Center Dept of Medicine
    Los Angeles, California 90048, United States
  • University of California, San Francisco- California
    San Francisco, California 94143, United States
  • Stanford University Stanford
    Stanford, California 94305, United States
  • Gainesville Heme Oncology Associates
    Gainesville, Florida 32607, United States
  • Baptist Cancer Institute
    Jacksonville, Florida 32207, United States
  • Integrated Community Oncology Network
    Orange Park, Florida 32073, United States
  • Gulf Coast Oncology
    Saint Petersburg, Florida 33705, United States
  • Palm Beach Cancer Institute, LLC
    West Palm Beach, Florida 33401, United States
  • Southern Illinois Hematology Oncology
    Centralia, Illinois 62801, United States
  • Orchard Healthcare Research, Inc.
    Chicago, Illinois 60611, United States
  • John H Stroger Hospital of Cook County
    Chicago, Illinois 60612, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Ingalls Cancer Institute
    Harvey, Illinois 60426-3558, United States
  • Cancer Center of Kansas
    Wichita, Kansas 67124, United States
  • Maine Center for Cancer Medicine Blood Disorders
    Scarborough, Maine 04074, United States
  • Center for Cancer and Blood Disorders
    Bethesda, Maryland 20817, United States
  • Mayo Clinic Cancer Center
    Rochester, Minnesota 55905, United States
  • Billings Clinic
    Billings, Montana 59107, United States
  • Arena Oncology Associates, PC
    Lake Success, New York 11042, United States
  • Dakota Cancer Institute
    Fargo, North Dakota 58103, United States
  • Gabrail Cancer Center Research
    Canton, Ohio 44718, United States
  • University Hospitals of Cleveland
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Kaiser Permanente Northwest Oncology Hematology
    Portland, Oregon 97227, United States
  • St. Luke's Hospital and Health Network
    Allentown, Pennsylvania 18104, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • The Cancer Center
    Collierville, Tennessee 38017, United States
  • University of Tennessee Cancer Institute
    Memphis, Tennessee 38104, United States
  • University of Texas Medical Branch
    Galveston, Texas 77555-0561, United States
  • Swedish Cancer Institute
    Seattle, Washington 98104, United States
  • Fred Hutchinson Cancer Center
    Seattle, Washington 98109, United States
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Peter MacCallum Cancer Centre Divsion of Haematology Medical Oncology
    E. Melbourne, Victoria 3002, Australia
  • Western Hospital
    Footscray, Victoria 3011, Australia
  • Frankston Hospital
    Frankston, Victoria 3199, Australia
  • Flinders Medical Centre
    Bedford Park, 5042, Australia
  • Geelong Hospital
    Geelong, 3220, Australia
  • Gosford Hospital
    Gosford, 2250, Australia
  • Royal Brisbane and Women's Hospital
    Herston, 4029, Australia
  • Cabrini Hospital
    Malvern, 3144, Australia
  • The Royal Melbourne Hospital
    Parkville, 3050, Australia
  • Royal Perth Hospital
    Perth, 6000, Australia
  • Gold Coast Hospital
    Southport, 4215, Australia
  • Royal North Shore Hospital
    St Leonards, 2065, Australia
  • Westmead Hospital
    Wentworthville, 2145, Australia
  • Border Medical Oncology
    Wodonga, 3690, Australia
  • Wollongong Hospital
    Wollongong, 2500, Australia
  • Princess Alexandra Hospital
    Woolloongabba, 4102, Australia
  • Hospital Leoben
    Leoben, 8700, Austria
  • Hospital of Barmherzige Schwestern Linz
    Linz, 4010, Austria
  • Hospital of Elisabethinen Linz
    Linz, 4010, Austria
  • General Hospital Linz
    Linz, 4021, Austria
  • MM-015. Salzburger Landkliniken, St. Johanns-Spital, Universitätsklinik fur Innere Medizin III
    Salzburg, 5020, Austria
  • Hospital St. Polten
    St. Pölten, 3100, Austria
  • Hospital of the Barmherzigen Bruder Vienna
    Vienna, 1020, Austria
  • MM-015.Wihelminenspital
    Vienna, 1160, Austria
  • MM-015. Medizinische Universität Wien
    Vienna, A-1090, Austria
  • Hospital Wels
    Wels, 4600, Austria
  • Hospital Wiener Neustadt
    Wiener Neustadt, Austria
  • ZNA Stuivenberg Centrumziekenhuis
    Antwerpen, 2069, Belgium
  • Les Cliniques du Sud Luxembourg
    Arlon, 6700, Belgium
  • AZ St-Jan Brugge Oostende AV
    Brugge, 8000, Belgium
  • Hopital Erasme
    Brussels, 1070, Belgium
  • AZ-VUB
    Brussels, 1090, Belgium
  • Jules Bordet Institut
    Brussel, 1000, Belgium
  • Cliniques Universitaires St-Luc
    Bruxelles, 1200, Belgium
  • Universitair Ziekenhuis Antwerpen
    Edegem, 2650, Belgium
  • UZ Gent
    Gent, 9000, Belgium
  • Virga Jesse Ziekenhuis
    Hasselt, 3500, Belgium
  • Universitair Ziekenhuis Leuven, Campus Gasthuisberg
    Leuven, 3000, Belgium
  • H. Hartziekenhuis Roeselare-Menen vzw campus Wilgenstraat
    Roeselare, 8800, Belgium
  • Cliniques Universitaires UCL de Mont-Godine
    Yvoir, 5530, Belgium
  • University of Calgary
    Calgary, Alberta T2N 2T9, Canada
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • British Columbia Cancer Agency
    Kelowna, British Columbia V1Y 5L3, Canada
  • Royal Columbian Hospital
    New Westminster, British Columbia V3M 1X4, Canada
  • BC Cancer Agency - Fraser Valley Centre
    Surrey, British Columbia V3V 1Z2, Canada
  • Leukemia/BMT Program of BCDiv of Hem, Vancouver Gen Hosp
    Vancouver, British Columbia V5Z 1M9, Canada
  • Vancouver Island Cancer Center
    Victoria, British Columbia V8R 6V5, Canada
  • Saint John Regional Hospital
    Saint John, New Brunswick E2L 3L6, Canada
  • Queen Elizabeth II Health Sciences Center
    Halifax, Nova Scotia B3H2Y9, Canada
  • Juravinski Cancer Centre
    Hamilton, Ontario L8V 5C2, Canada
  • London Health Science Centre
    London, Ontario N6A 4G5, Canada
  • Ottawa Hospital
    Ottawa, Ontario K1H 8L6, Canada
  • Odette Cancer Centre
    Toronto, Ontario M4N 3M5, Canada
  • Princess Margaret Hospital
    Toronto, Ontario M5G 2M9, Canada
  • Hospital Charles LeMoyne
    Greenfield Park, Quebec J4V 2H1, Canada
  • Hopital de la Cite-de-la-Sante
    Laval, Quebec H7M 3L9, Canada
  • Hotel-Dieu de Levis
    Levis, Quebec G5V 3Z1, Canada
  • Hopital du Sacre-Coeur de Montreal
    Montreal, Quebec G4H 1C5, Canada
  • Hospital Maisonneuve - Rosemont
    Montreal, Quebec H1T 2M4, Canada
  • CHUM- Hopital Notre-Dame
    Montreal, Quebec H2L4M1, Canada
  • McGill University
    Montreal, Quebec H2W 1S6, Canada
  • Sir Mortimer B. Davis - Jewish Genl
    Montreal, Quebec H3T 1E2, Canada
  • CHUQ - Hotel-Dieu de QuebecHematology - Oncology
    Quebec, G1R 2J6, Canada
  • Chaoyang Hospital
    Beijing, 100020, China
  • Peking University People's Hospital
    Beijing, 100044, China
  • West China Hospital of Sichuan University
    Chengdu, 610041, China
  • Ruijin Hospital Shanghai Jiaotong University
    Shanghai, 200025, China

Showing the first 100 of 288 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Dimopoulos MA, Cheung MC, Roussel M, Liu T, Gamberi B, Kolb B, Derigs HG, Eom H, Belhadj K, Lenain P, Van der Jagt R, Rigaudeau S, Dib M, Hall R, Jardel H, Jaccard A, Tosikyan A, Karlin L, Bensinger W, Schots R, Leupin N, Chen G, Marek J, Ervin-Haynes A, Facon T. Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. Haematologica. 2016 Mar;101(3):363-70. doi: 10.3324/haematol.2015.133629. Epub 2015 Dec 11. PubMed 26659916 ↗
  • Hulin C, Belch A, Shustik C, Petrucci MT, Duhrsen U, Lu J, Song K, Rodon P, Pegourie B, Garderet L, Hunter H, Azais I, Eek R, Gisslinger H, Macro M, Dakhil S, Goncalves C, LeBlanc R, Romeril K, Royer B, Doyen C, Leleu X, Offner F, Leupin N, Houck V, Chen G, Ervin-Haynes A, Dimopoulos MA, Facon T. Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial. J Clin Oncol. 2016 Oct 20;34(30):3609-3617. doi: 10.1200/JCO.2016.66.7295. PubMed 27325857 ↗
  • Delforge M, Minuk L, Eisenmann JC, Arnulf B, Canepa L, Fragasso A, Leyvraz S, Langer C, Ezaydi Y, Vogl DT, Giraldo-Castellano P, Yoon SS, Zarnitsky C, Escoffre-Barbe M, Lemieux B, Song K, Bahlis NJ, Guo S, Monzini MS, Ervin-Haynes A, Houck V, Facon T. Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide. Haematologica. 2015 Jun;100(6):826-33. doi: 10.3324/haematol.2014.120121. Epub 2015 Mar 13. PubMed 25769541 ↗
  • Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldes C, Lee JJ, Chen C, Oriol A, de la Rubia J, Qiu L, White DJ, Binder D, Anderson K, Fermand JP, Moreau P, Attal M, Knight R, Chen G, Van Oostendorp J, Jacques C, Ervin-Haynes A, Avet-Loiseau H, Hulin C, Facon T; FIRST Trial Team. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014 Sep 4;371(10):906-17. doi: 10.1056/NEJMoa1402551. PubMed 25184863 ↗
  • Vogl DT, Delforge M, Song K, Guo S, Gibson CJ, Ervin-Haynes A, Facon T. Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone. Leuk Lymphoma. 2018 Feb;59(2):398-405. doi: 10.1080/10428194.2017.1334125. Epub 2017 Jun 22. PubMed 28641472 ↗
  • Dumontet C, Hulin C, Dimopoulos MA, Belch A, Dispenzieri A, Ludwig H, Rodon P, Van Droogenbroeck J, Qiu L, Cavo M, Van de Velde A, Lahuerta JJ, Allangba O, Lee JH, Boyle E, Perrot A, Moreau P, Manier S, Attal M, Roussel M, Mohty M, Mary JY, Civet A, Costa B, Tinel A, Gaston-Mathe Y, Facon T. A predictive model for risk of early grade >/= 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. Leukemia. 2018 Jun;32(6):1404-1413. doi: 10.1038/s41375-018-0133-x. Epub 2018 Apr 26. PubMed 29784907 ↗
  • Ailawadhi S, Jacobus S, Sexton R, Stewart AK, Dispenzieri A, Hussein MA, Zonder JA, Crowley J, Hoering A, Barlogie B, Orlowski RZ, Rajkumar SV. Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer J. 2018 Jul 6;8(7):67. doi: 10.1038/s41408-018-0102-7. PubMed 29980678 ↗
  • Jain T, Sonbol MB, Firwana B, Kolla KR, Almader-Douglas D, Palmer J, Fonseca R. High-Dose Chemotherapy with Early Autologous Stem Cell Transplantation Compared to Standard Dose Chemotherapy or Delayed Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis. Biol Blood Marrow Transplant. 2019 Feb;25(2):239-247. doi: 10.1016/j.bbmt.2018.09.021. Epub 2018 Sep 20. PubMed 30244101 ↗
  • Facon T, Dimopoulos MA, Dispenzieri A, Catalano JV, Belch A, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis NJ, Banos A, Tiab M, Delforge M, Cavenagh JD, Geraldes C, Lee JJ, Chen C, Oriol A, De La Rubia J, White D, Binder D, Lu J, Anderson KC, Moreau P, Attal M, Perrot A, Arnulf B, Qiu L, Roussel M, Boyle E, Manier S, Mohty M, Avet-Loiseau H, Leleu X, Ervin-Haynes A, Chen G, Houck V, Benboubker L, Hulin C. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018 Jan 18;131(3):301-310. doi: 10.1182/blood-2017-07-795047. Epub 2017 Nov 17. PubMed 29150421 ↗
  • Ailawadhi S, DerSarkissian M, Duh MS, Lafeuille MH, Posner G, Ralston S, Zagadailov E, Ba-Mancini A, Rifkin R. Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma. Clin Ther. 2019 Mar;41(3):477-493.e7. doi: 10.1016/j.clinthera.2019.01.009. Epub 2019 Feb 14. PubMed 30773308 ↗
  • Pegourie B, Karlin L, Benboubker L, Orsini-Piocelle F, Tiab M, Auger-Quittet S, Rodon P, Royer B, Leleu X, Bareau B, Cliquennois M, Fuzibet JG, Voog E, Belhadj-Merzoug K, Decaux O, Rey P, Slama B, Leyronnas C, Zarnitsky C, Boyle E, Bosson JL, Pernod G; IFM Group. Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study. Am J Hematol. 2019 Jun;94(6):635-640. doi: 10.1002/ajh.25459. Epub 2019 Apr 1. PubMed 30859608 ↗
  • Bahlis NJ, Corso A, Mugge LO, Shen ZX, Desjardins P, Stoppa AM, Decaux O, de Revel T, Granell M, Marit G, Nahi H, Demuynck H, Huang SY, Basu S, Guthrie TH, Ervin-Haynes A, Marek J, Chen G, Facon T. Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial. Leukemia. 2017 Nov;31(11):2435-2442. doi: 10.1038/leu.2017.111. Epub 2017 Apr 4. PubMed 28373701 ↗
  • Lu J, Lee JH, Huang SY, Qiu L, Lee JJ, Liu T, Yoon SS, Kim K, Shen ZX, Eom HS, Chen WM, Min CK, Kim HJ, Lee JO, Kwak JY, Yiu W, Chen G, Ervin-Haynes A, Hulin C, Facon T. Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial. Br J Haematol. 2017 Mar;176(5):743-749. doi: 10.1111/bjh.14465. Epub 2017 Jan 20. PubMed 28106903 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2008 to primary completion in Jul 2016, 94 months.

Results were first posted in Aug 2017, 1 year after primary completion.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 94 months is above that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2008
First posted
Jun 4, 2008
StartActual
Aug 21, 2008
Primary completionActual
Jul 14, 2016
CompletionActual
Jul 14, 2016
Results first posted
Aug 11, 2017
Last update
Nov 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00689936
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Jun 4, 2008
Start date
Aug 21, 2008
Primary completion
Jul 14, 2016
Completion
Jul 14, 2016
Results posted
Aug 11, 2017
Last update
Nov 20, 2019

Study contacts

Christian Jacques, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lenalidomide · Dexamethasone

Start the discussion